- Tytuł:
- Long-term outcomes with HLX01 (HanliKang), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
- Autorzy:
- Źródło:
- BMC Cancer. Dec2024, Vol. 24 Issue 1, p1-10. 10p.
Czasopismo naukowe